CytoSorbents Investor Relations
CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with more than 300,000 CytoSorb® devices sold in more than 70 countries to date, and seeking U.S. FDA market authorization for an investigational product, DrugSorb-ATR®, to remove blood thinning drugs.
Featured News
CytoSorbents
Press Release
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
PRINCETON, N.J., Sept. 30, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart surgery at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain from October ... CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
PRINCETON, N.J., Sept. 23, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with the Nasdaq Stock Market’s minimum bid price requirement of $1.00 per share. CytoSorbents Regains Compliance with Nasdaq Minimum ... CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
PRINCETON, N.J., Sept. 10, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14–16, 2026, in New York City. Dr. ... CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Princeton, New Jersey–(Newsfile Corp. – September 4, 2026) – CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, ... CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
